Eli Lilly & Co. (LLY) Q4 2011 Earnings Call January 31, 2012 9:00 am ET Executives Ronika Pletcher - Ilissa Rassner - Derica W. Rice - Chief Financial Officer, Executive Vice President of Global Services and Member of Policy & Strategy Committee Philip Johnson - Jan M. Lundberg - Executive Vice President of Science & Technology and President of Lilly Research Laboratories John C. Lechleiter - Chairman, Chief Executive Officer and President Jeffrey N. Simmons - Senior Vice President and Head of Elanco Animal Health Business Unit Analysts Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division Jami Rubin - Goldman Sachs Group Inc., Research Division Marc Goodman - UBS Investment Bank, Research Division Gregory B. Gilbert - BofA Merrill Lynch, Research Division David Risinger - Morgan Stanley, Research Division Steve Scala - Cowen and Company, LLC, Research Division John T. Boris - Citigroup Inc, Research Division Charles Anthony Butler - Barclays Capital, Research Division Seamus Fernandez - Leerink Swann LLC, Research Division Jeffrey Holford - Jefferies & Company, Inc., Research Division Christopher Schott - JP Morgan Chase & Co, Research Division Catherine J. Arnold - Crédit Suisse AG, Research Division PresentationOperator
Ladies and gentlemen, thank you for standing by, and welcome to the Q4 earnings call. [Operator Instructions] And as a reminder, today's conference call is being recorded. I would now like to turn the conference over to Ronika Pletcher, Director of Investor Relations. Please go ahead. Ronika Pletcher Good morning. Thank you for taking the time to join us for Eli Lilly & Co.'s Fourth Quarter 2011 Earnings Conference Call. I'm Ronika Pletcher, Director of Investor Relations. Joining me are our Chairman and CEO, John Lechleiter; our Chief Financial Officer, Derica Rice; our President of Lilly Research Laboratories, Dr. Jan Lundberg; our President of Elanco Animal Health, Jeff Simmons; and Ilissa Rassner and Phil Johnson from Investor Relations.